Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Incyte (INCY) PT Raised to $140 at Jefferies on 4Q Report, Jakafi Metrics
February 15, 2017 8:10 AM ESTJefferies analyst Brian Abrahams reiterates Buy rating and raises price target on Incyte Corp. (NASDAQ: INCY) to $140 (from $136) as the company delivered in-line Jakafi sales figures, while offering positive guidance.
Abrahams comments, "Solid, unsurprising Valentine's Day 4Q report, with good Jakafi metrics and... More
RBC Capital Reiterates Outperform Rating on Incyte (INCY) Following 4Q Results
February 14, 2017 9:37 AM ESTRBC Capital Markets analyst Simos Simeonidis reiterates Outperform rating on Incyte Corporation (NASDAQ: INCY) suggesting Jakafi continues to grow, despite the company reporting 2016 fourth quarter revenues below consensus.
Simeonidis comments, INCY reported slightly below consensus Jakafi/total revenue numbers, despite decent growth five years... More
Incyte (INCY) Misses Q4 EPS by 8c
February 14, 2017 7:11 AM ESTIncyte (NASDAQ: INCY) reported Q4 EPS of $0.05, $0.08 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $326 million versus the consensus estimate of $324.42 million.
For earnings history and earnings-related data on Incyte (INCY) click here.
... More